Landscape → Ophthalmology

Age-Related Macular Degeneration Clinical Trial Landscape

Data updated: May 20, 2026

544 clinical trials tracked since 2008

Age-Related Macular Degeneration is being studied across 544 clinical trials registered since 2008, with 136 programs currently active. The competitive pipeline includes 39 active Phase 3 trials, 65 active Phase 2 trials, and 56 active Phase 1 trials. Top industry sponsors include Roche, AbbVie, EyeBiotech Ltd..

136 active

544 total (since 2008)

Phase 1 Active

181 total

Phase 2 Active

246 total

Phase 3 Active

130 total

Phase 4 Active

82 total

Top Industry Sponsors

Sorted by active Active Done Failed

Roche 9 9 3

AbbVie 6 10 2

EyeBiotech Ltd. 4 1 0

Chengdu Origen Biotechnology Co., Ltd. 4 0 0

Ocular Therapeutix, Inc. 3 2 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT07007065 RECRUITING

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

AbbVie n=561

NCT06541704 RECRUITING

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Regeneron Pharmaceuticals n=975

NCT04657289 ACTIVE NOT RECRUITING

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Hoffmann-La Roche n=451

NCT06668064 ACTIVE NOT RECRUITING

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

EyePoint Pharmaceuticals, Inc. n=400

NCT07440225 RECRUITING

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

EyeBiotech Ltd. n=960

+ 125 more Phase 3 trials — see full database below

Age-Related Macular Degeneration — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Roche

AbbVie

EyeBiotech Ltd.

Chengdu Origen Biotechnology Co., Ltd.

Ocular Therapeutix, Inc.

Adverum Biotechnologies, Inc.

4D Molecular Therapeutics

Innostellar Biotherapeutics Co.,Ltd

Novartis

Regeneron

Active Trials by Phase

Phase 1

Phase 2

Phase 3

Phase 4

Enrollment Size Distribution

1-50

252

51-200

144

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Roche 9 9 3

AbbVie 6 10 2

EyeBiotech Ltd. 4 1 0

Chengdu Origen Biotechnology Co., Ltd. 4 0 0

Ocular Therapeutix, Inc. 3 2 0

Adverum Biotechnologies, Inc. 3 1 0

4D Molecular Therapeutics 3 0 0

Innostellar Biotherapeutics Co.,Ltd 3 0 0

Novartis 2 34 6

Regeneron 2 7 1

EyePoint Pharmaceuticals, Inc. 2 2 0

Alkeus Pharmaceuticals, Inc. 2 2 0

AiViva BioPharma, Inc. 2 1 0

Beijing Anlong Biopharmaceutical Co., Ltd. 2 0 0

Frontera Therapeutics 2 0 0

NCT07007065 RECRUITING

AbbVie n=561

NCT06541704 RECRUITING

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Regeneron Pharmaceuticals n=975

NCT04657289 ACTIVE NOT RECRUITING

Hoffmann-La Roche n=451

NCT06668064 ACTIVE NOT RECRUITING

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

EyePoint Pharmaceuticals, Inc. n=400

NCT07440225 RECRUITING

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

EyeBiotech Ltd. n=960

NCT07496567 RECRUITING

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

EyeBiotech Ltd. n=960

NCT06683742 ACTIVE NOT RECRUITING

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

EyePoint Pharmaceuticals, Inc. n=400

NCT05562947 RECRUITING

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Hoffmann-La Roche n=68

NCT06556368 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Kodiak Sciences Inc n=675

NCT07482176 RECRUITING

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Adverum Biotechnologies, Inc. n=284

NCT04704921 ACTIVE NOT RECRUITING

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

AbbVie n=671

NCT06847542 RECRUITING

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Hoffmann-La Roche n=250

NCT03683251 RECRUITING

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Hoffmann-La Roche n=1,000

NCT05112861 ACTIVE NOT RECRUITING

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

Outlook Therapeutics, Inc. n=120

NCT05407636 RECRUITING

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

AbbVie n=714

NCT07064759 RECRUITING

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

4D Molecular Therapeutics n=480

NCT07520318 NOT YET RECRUITING

This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.

Shenzhen Oculgen Biomedical Technology Co., Ltd. n=255

NCT07269769 NOT YET RECRUITING

A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD

Tasly Pharmaceutical Group Co., Ltd n=450

NCT07516132 NOT YET RECRUITING

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Ocular Therapeutix, Inc. n=850

NCT06864988 ACTIVE NOT RECRUITING

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

4D Molecular Therapeutics n=480

NCT07489586 NOT YET RECRUITING

A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration

Qilu Pharmaceutical Co., Ltd. n=356

NCT07461441 RECRUITING

Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy

Yeungnam University College of Medicine n=50

NCT07317934 RECRUITING

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Innostellar Biotherapeutics Co.,Ltd n=332

NCT04663750 RECRUITING

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

King's College Hospital NHS Trust n=210

NCT05904028 RECRUITING

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Jaeb Center for Health Research n=600

NCT06952452 RECRUITING

Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)

Parc de Salut Mar n=630

NCT06856577 RECRUITING

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. n=284

NCT06373731 ACTIVE NOT RECRUITING

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Stealth BioTherapeutics Inc. n=313

NCT06491914 ACTIVE NOT RECRUITING

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Regeneron Pharmaceuticals n=1,118

NCT07189169 RECRUITING

QA108 Phase III Study in Subjects With Intermediate AMD

Smilebiotek Zhuhai Limited n=400

NCT07129239 NOT YET RECRUITING

High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)

Clinique de Retine de l'est n=180

NCT06495918 ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Ocular Therapeutix, Inc. n=825

NCT06305416 RECRUITING

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Incepta Pharmaceuticals Ltd n=70

NCT06223958 ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Ocular Therapeutix, Inc. n=344

NCT06470373 NOT YET RECRUITING

A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration

Rophibio, Inc. n=434

NCT05972473 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Innovent Biologics (Suzhou) Co. Ltd. n=600

NCT05461339 ACTIVE NOT RECRUITING

TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

BioDlink Biopharm Co., Ltd. n=488

NCT06165068 RECRUITING

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

Navamindradhiraj University n=174

NCT05251636 NOT YET RECRUITING

Adjunct Episcleral Brachytherapy for PCV

Salutaris Medical Devices, Inc. n=159

NCT05536297 COMPLETED

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Astellas Pharma Global Development, Inc. n=278

NCT07389577 COMPLETED

A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)

Jecho Biopharmaceuticals Co., Ltd. n=443

NCT04690556 COMPLETED

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Lupin Ltd. n=600

NCT07214740 COMPLETED

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

Apellis Pharmaceuticals, Inc. n=44

NCT05439629 COMPLETED

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Bio-Thera Solutions n=488

NCT04522167 COMPLETED

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

Bioeq GmbH n=434

NCT03845582 COMPLETED

Phase 2/3 Study of ALK-001 in Geographic Atrophy

Alkeus Pharmaceuticals, Inc. n=200

NCT04770545 COMPLETED

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

Apellis Pharmaceuticals, Inc. n=792

NCT04777201 COMPLETED

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Hoffmann-La Roche n=1,036

NCT04435366 COMPLETED

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

IVERIC bio, Inc. n=448

NCT04270747 COMPLETED

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Amgen n=576

NCT04423718 COMPLETED

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

Bayer n=1,011

NCT02243878 COMPLETED

Stereotactic Radiotherapy for Wet AMD (STAR)

King's College Hospital NHS Trust n=411

NCT04757636 TERMINATED

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

Opthea Limited n=998

NCT03823287 COMPLETED

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Hoffmann-La Roche n=671

NCT04757610 TERMINATED

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

Opthea Limited n=986

NCT03823300 COMPLETED

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Hoffmann-La Roche n=658

NCT02686658 COMPLETED

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

IVERIC bio, Inc. n=286

NCT05989126 COMPLETED

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Regeneron Pharmaceuticals n=35

NCT05604989 COMPLETED

Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration

Seoul National University Bundang Hospital n=45

NCT05003245 COMPLETED

Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Shanghai Henlius Biotech n=407

NCT03844074 COMPLETED

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Outlook Therapeutics, Inc. n=61

NCT03834753 COMPLETED

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Outlook Therapeutics, Inc. n=228

NCT04516278 COMPLETED

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

Outlook Therapeutics, Inc. n=195

NCT06190093 COMPLETED

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)

Outlook Therapeutics, Inc. n=400

NCT02307682 COMPLETED

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

Alcon Research n=1,775

NCT02434328 COMPLETED

Efficacy and Safety of RTH258 Versus Aflibercept - Study 2

Alcon Research n=1,048

NCT04740671 COMPLETED

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Shanghai Henlius Biotech n=410

NCT04047472 COMPLETED

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Novartis Pharmaceuticals n=397

NCT04264819 COMPLETED

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

Novartis Pharmaceuticals n=295

NCT01940887 TERMINATED

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Ophthotech Corporation n=645

NCT01944839 TERMINATED

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Ophthotech Corporation n=619

NCT01940900 TERMINATED

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Ophthotech Corporation n=627

NCT04597632 COMPLETED

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

Novartis Pharmaceuticals n=248

NCT04239027 COMPLETED

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration

Novartis Pharmaceuticals n=210

NCT04005352 COMPLETED

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Novartis Pharmaceuticals n=734

NCT05155293 COMPLETED

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

Alvotech Swiss AG n=413

NCT04049266 TERMINATED

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Kodiak Sciences Inc n=559

NCT04964089 COMPLETED

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Kodiak Sciences Inc n=557

NCT04864834 COMPLETED

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

Sandoz n=485

NCT04450329 COMPLETED

A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Samsung Bioepis Co., Ltd. n=449

NCT05126966 WITHDRAWN

A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

Hoffmann-La Roche

NCT03805100 COMPLETED

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD

Xbrane Biopharma AB n=582

NCT04480463 COMPLETED

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Sam Chun Dang Pharm. Co. Ltd. n=576

NCT05569148 COMPLETED

A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe

Hoffmann-La Roche n=35

NCT05282004 COMPLETED

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Sandoz n=36

NCT01436864 COMPLETED

A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD

Chengdu Kanghong Biotech Co., Ltd. n=125

NCT05587062 COMPLETED

Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Cinnagen n=168

NCT03710564 TERMINATED

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

Novartis Pharmaceuticals n=535

NCT04636853 COMPLETED

CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration

Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=20

NCT02157077 COMPLETED

Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration

Centre Hospitalier Intercommunal Creteil n=90

NCT05161806 COMPLETED

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

Sandoz n=30

NCT03677934 COMPLETED

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

Hoffmann-La Roche n=415

NCT05345236 COMPLETED

A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)

Qilu Pharmaceutical Co., Ltd. n=366

NCT02611778 COMPLETED

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration

Bioeq GmbH n=712

NCT04697953 WITHDRAWN

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

Novartis Pharmaceuticals

NCT03577899 TERMINATED

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

Chengdu Kanghong Biotech Co., Ltd. n=1,157

NCT03630952 TERMINATED

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

Chengdu Kanghong Biotech Co., Ltd. n=1,157

NCT02540954 COMPLETED

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Bayer n=336

NCT03150589 COMPLETED

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Samsung Bioepis Co., Ltd. n=705

NCT04857177 COMPLETED

A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

Chong Kun Dang Pharmaceutical n=312

NCT03954626 COMPLETED

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

Novartis Pharmaceuticals n=14

NCT03386474 COMPLETED

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

Novartis Pharmaceuticals n=151

NCT03930641 COMPLETED

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Novartis Pharmaceuticals n=34

NCT03668054 COMPLETED

Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

Laboratorio Elea Phoenix S.A. n=22

NCT02032173 TERMINATED

Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase

Novartis Pharmaceuticals n=31

NCT00764738 COMPLETED

Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

Retina Macula Institute n=91

NCT02462486 COMPLETED

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Allergan n=949

NCT02462928 COMPLETED

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Allergan n=939

NCT01835067 COMPLETED

Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD

King's College Hospital NHS Trust n=55

NCT03034772 COMPLETED

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

Wills Eye n=52

NCT01402544 TERMINATED

Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

University of California, San Diego n=20

NCT01748292 COMPLETED

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

Charles C Wykoff, PhD, MD n=60

NCT01170767 COMPLETED

French Evaluation Group Avastin Versus Lucentis

Hospices Civils de Lyon n=501

NCT00593450 COMPLETED

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial

University of Pennsylvania n=1,208

NCT01780935 COMPLETED

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration

Novartis Pharmaceuticals n=671

NCT01948830 COMPLETED

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

Novartis Pharmaceuticals n=650

NCT00826371 COMPLETED

Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients

Novartis Pharmaceuticals n=114

NCT01482910 COMPLETED

VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

Bayer n=304

NCT00964795 COMPLETED

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

Regeneron Pharmaceuticals n=323

NCT00557791 WITHDRAWN

Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)

OPKO Health, Inc.

NCT02035722 COMPLETED

Intravitreal Injections-related Anxiety

University Health Network, Toronto n=73

NCT00637377 COMPLETED

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

Bayer n=1,240

NCT00769015 COMPLETED

Low Vision Depression Prevention Trial for Age Related Macular Degeneration

Thomas Jefferson University n=188

NCT00890097 TERMINATED

Geographic Atrophy Treatment Evaluation

Alcon Research n=772

NCT01601483 TERMINATED

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

MacuCLEAR, Inc. n=22

NCT01269697 COMPLETED

Lutein Influence on Macula of Persons Issued From Amd Parents

University Hospital, Bordeaux n=120

NCT00891735 COMPLETED

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

Genentech, Inc. n=1,097

NCT00599222 COMPLETED

The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study

Anders Kvanta n=100

NCT01327222 COMPLETED

Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)

IRCCS San Raffaele n=20

NCT00709449 COMPLETED

An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects

Medical University of Vienna n=60

NCT07441642 RECRUITING

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Novartis Pharmaceuticals

NCT06635148 RECRUITING

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Janssen Research & Development, LLC

NCT04567303 ACTIVE NOT RECRUITING

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

Hoffmann-La Roche

NCT07392255 RECRUITING

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Complement Therapeutics

NCT06765980 RECRUITING

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Kriya Therapeutics, Inc.

NCT07557121 NOT YET RECRUITING

Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

AiViva BioPharma, Inc.

NCT07547228 RECRUITING

A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

Intra-IMMUSG Pte Ltd

NCT02286089 ACTIVE NOT RECRUITING

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

Hoffmann-La Roche

NCT06990269 RECRUITING

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

ADARx Pharmaceuticals, Inc.

NCT04504123 RECRUITING

MMP-9 Inhibition for Recalcitrant Wet AMD

University of Iowa

NCT07215390 RECRUITING

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Apellis Pharmaceuticals, Inc.

NCT07501052 NOT YET RECRUITING

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

Sam Chun Dang Pharm. Co. Ltd.

NCT06557460 RECRUITING

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Regenerative Patch Technologies, LLC

NCT06664502 ACTIVE NOT RECRUITING

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

EyeBiotech Ltd.

NCT06196840 ACTIVE NOT RECRUITING

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Innostellar Biotherapeutics Co.,Ltd

NCT04514653 ACTIVE NOT RECRUITING

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

AbbVie

NCT07418177 NOT YET RECRUITING

Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD

The First Affiliated Hospital with Nanjing Medical University

NCT07160179 RECRUITING

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

AbbVie

NCT05197270 RECRUITING

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

4D Molecular Therapeutics

NCT06550011 ACTIVE NOT RECRUITING

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Avirmax Biopharma Inc

NCT04339764 RECRUITING

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

National Eye Institute (NEI)

NCT04292080 RECRUITING

Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy

Assistance Publique - Hôpitaux de Paris

NCT06722157 ACTIVE NOT RECRUITING

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Boehringer Ingelheim

NCT04735263 RECRUITING

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

Massachusetts Eye and Ear Infirmary

NCT07158775 RECRUITING

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Bionic Sight LLC

NCT05984927 ACTIVE NOT RECRUITING

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

Elisigen, Inc.

NCT07275840 RECRUITING

A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

Innovent Biologics Technology Limited (Shanghai R&D Center)

NCT05769153 ACTIVE NOT RECRUITING

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Alcon Research

NCT06164587 ACTIVE NOT RECRUITING

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

Michelle Abou-Jaoude

NCT05170048 NOT YET RECRUITING

Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD

Evergreen Therapeutics, Inc.

NCT06659445 RECRUITING

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

ONL Therapeutics

NCT06467344 RECRUITING

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Ascidian Therapeutics, Inc

NCT06660667 RECRUITING

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

Sanofi

NCT04101877 ACTIVE NOT RECRUITING

The Sahlgrenska Anti-VEGF Study

Vastra Gotaland Region

NCT05839041 ACTIVE NOT RECRUITING

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Aviceda Therapeutics, Inc.

NCT07205887 RECRUITING

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

EyeBiotech Ltd.

NCT06116890 ACTIVE NOT RECRUITING

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Kyowa Kirin Co., Ltd.

NCT04627428 RECRUITING

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Luxa Biotechnology, LLC

NCT06087458 RECRUITING

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Perceive Biotherapeutics, Inc.

NCT07185841 RECRUITING

Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

Fujian Haixi Pharmaceuticals Co., Ltd.

NCT07178249 NOT YET RECRUITING

Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD

Guangzhou Jiayin Biotech Ltd

NCT05536973 ACTIVE NOT RECRUITING

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

Adverum Biotechnologies, Inc.

NCT05230537 ACTIVE NOT RECRUITING

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Novartis Pharmaceuticals

NCT05387837 ACTIVE NOT RECRUITING

Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

Ashvattha Therapeutics, Inc.

NCT06942572 RECRUITING

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

Splice Bio

NCT04239625 ACTIVE NOT RECRUITING

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Alkeus Pharmaceuticals, Inc.

NCT02402660 ENROLLING BY INVITATION

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Alkeus Pharmaceuticals, Inc.

NCT06787482 RECRUITING

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

Ace Cells Lab Limited

NCT06707753 ACTIVE NOT RECRUITING

Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD

Beijing Anlong Biopharmaceutical Co., Ltd.

NCT06839339 NOT YET RECRUITING

Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD

Beijing Anlong Biopharmaceutical Co., Ltd.

NCT05986864 RECRUITING

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Skyline Therapeutics (US) Inc.

NCT06458595 RECRUITING

Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Chengdu Origen Biotechnology Co., Ltd.

NCT05672121 RECRUITING

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Chengdu Origen Biotechnology Co., Ltd.

NCT06141460 RECRUITING

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Shanghai Refreshgene Technology Co., Ltd.

NCT06394232 RECRUITING

Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

Eyestem Research Pvt. Ltd.

NCT06487039 RECRUITING

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

EyebioKorea, Inc.

NCT06492863 RECRUITING

Gene Therapy(FT-003) for Wet AMD

Frontera Therapeutics

NCT03999801 ENROLLING BY INVITATION

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

AbbVie

NCT05859776 ACTIVE NOT RECRUITING

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

AsclepiX Therapeutics, Inc.

NCT05481827 ENROLLING BY INVITATION

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

Gyroscope Therapeutics Limited

NCT07587515 NOT YET RECRUITING

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Eyconis INC.

NCT07550504 COMPLETED

A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV

Samsung Bioepis Co., Ltd.

NCT05637255 COMPLETED

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

Sylentis, S.A.

NCT06704009 COMPLETED

NT-101 Topical Ophthalmic Solution in Patients With Wet AMD

NexThera Co., Ltd.

NCT04566445 TERMINATED

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Gyroscope Therapeutics Limited

NCT03846193 TERMINATED

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Gyroscope Therapeutics Limited

NCT04437368 TERMINATED

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Gyroscope Therapeutics Limited

NCT05919693 COMPLETED

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

EyeBiotech Ltd.

NCT02564978 COMPLETED

Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration

National Eye Institute (NEI)

NCT02462889 COMPLETED

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

Jeffrey S Heier

NCT05381948 COMPLETED

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

EyePoint Pharmaceuticals, Inc.

NCT05265624 COMPLETED

The Moran AMD Genetic Testing Assessment Study

Paul S. Bernstein

NCT03022318 COMPLETED

Carbidopa-levodopa in Neovascular AMD

Snyder, Robert W., M.D., Ph.D., P.C.

NCT03023059 COMPLETED

Dose Ranging Study of Carbidopa-levodopa

Snyder, Robert W., M.D., Ph.D., P.C.

NCT05062486 COMPLETED

A Study to Evaluate the Safety and Efficacy of RQC for AMD

Paul A Knepper, MD PhD

NCT07093385 COMPLETED

Intravitreal Faricimab in Patients With Refractory Macular Edema

University of Baghdad

NCT05891548 COMPLETED

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

Clearside Biomedical, Inc.

NCT04356716 COMPLETED

Sildenafil for Treatment of Choroidal Ischemia

Columbia University

NCT03362190 COMPLETED

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Ophthotech Corporation

NCT02659098 COMPLETED

A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy

Janssen Research & Development, LLC

NCT05893537 TERMINATED

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Cognition Therapeutics

NCT05571267 TERMINATED

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

IVERIC bio, Inc.

NCT03815825 COMPLETED

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Ionis Pharmaceuticals, Inc.

NCT02895815 WITHDRAWN

Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Janssen Pharmaceutical K.K.

NCT05536752 COMPLETED

QA102 Phase II Study in Subjects With Dry AMD

Smilebiotek Zhuhai Limited

NCT06176963 COMPLETED

A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO

Samsung Bioepis Co., Ltd.

NCT03861234 COMPLETED

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Boehringer Ingelheim

NCT04820452 COMPLETED

A Study of IBI302 in Patients With nAMD

Innovent Biologics (Suzhou) Co. Ltd.

NCT01344993 COMPLETED

Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration

Astellas Institute for Regenerative Medicine

NCT02387957 TERMINATED

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Ophthotech Corporation

NCT04832724 COMPLETED

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

AbbVie

NCT05275205 COMPLETED

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

Unity Biotechnology, Inc.

NCT05562219 COMPLETED

QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration

Smilebiotek Zhuhai Limited

NCT03891875 COMPLETED

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA

Stealth BioTherapeutics Inc.

NCT05403749 COMPLETED

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Innovent Biologics (Suzhou) Co. Ltd.

NCT03451500 TERMINATED

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

Snyder, Robert W., M.D., Ph.D., P.C.

NCT05141994 COMPLETED

Clinical Study on the Efficacy and Safety of BAT5906 Injection

Bio-Thera Solutions

NCT01674829 TERMINATED

A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD

CHABiotech CO., Ltd

NCT04304755 COMPLETED

Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)

Oslo University Hospital

NCT03972709 TERMINATED

A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Genentech, Inc.

NCT04746963 TERMINATED

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration

AsclepiX Therapeutics, Inc.

NCT01089517 COMPLETED

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Ophthotech Corporation

NCT02214628 TERMINATED

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Ophthotech Corporation

NCT04993352 COMPLETED

Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD

Shanghai Henlius Biotech

NCT04607148 TERMINATED

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Genentech, Inc.

NCT04626128 COMPLETED

Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD

Clearside Biomedical, Inc.

NCT04126317 COMPLETED

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Regeneron Pharmaceuticals

NCT05961007 SUSPENDED

Evaluation of IBI302 Injection in nAMD or DME

Innovent Biologics (Suzhou) Co. Ltd.

NCT02684578 COMPLETED

Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

University of California, San Francisco

NCT04640272 COMPLETED

A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration

Ribomic USA Inc

NCT04200248 COMPLETED

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

Ribomic USA Inc

NCT02914639 COMPLETED

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

OcuTerra Therapeutics, Inc.

NCT03066258 COMPLETED

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

REGENXBIO Inc.

NCT04895293 COMPLETED

RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration

Maturi, Raj K., M.D., P.C.

NCT04486963 COMPLETED

A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects

Tasly Pharmaceutical Group Co., Ltd

NCT04684394 TERMINATED

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

Gemini Therapeutics, Inc.

NCT04331730 COMPLETED

A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

Alkahest, Inc.

NCT04643886 TERMINATED

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

Gemini Therapeutics, Inc.

NCT02140151 COMPLETED

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

Southern California Desert Retina Consultants, MC

NCT03725501 COMPLETED

Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD

AngioLab, Inc.

NCT02228304 TERMINATED

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Neurotech Pharmaceuticals

NCT02348359 TERMINATED

X-82 to Treat Age-related Macular Degeneration

Tyrogenex

NCT03953079 COMPLETED

A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

Graybug Vision

NCT04270669 COMPLETED

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

RemeGen Co., Ltd.

NCT03211234 COMPLETED

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Santen Inc.

NCT01445548 COMPLETED

Sirolimus for Advanced Age-Related Macular Degeneration

National Eye Institute (NEI)

NCT04358471 WITHDRAWN

Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)

Hemera Biosciences

NCT02510794 COMPLETED

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

Genentech, Inc.

NCT03869684 TERMINATED

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

Senju Pharmaceutical Co., Ltd.

NCT03452527 TERMINATED

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Iconic Therapeutics, Inc.

NCT03345082 COMPLETED

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Opthea Limited

NCT03633084 COMPLETED

RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration

Ribomic USA Inc

NCT01527500 COMPLETED

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

Novartis Pharmaceuticals

NCT03038880 COMPLETED

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

Hoffmann-La Roche

NCT03558074 COMPLETED

Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration

Alkahest, Inc.

NCT01535950 COMPLETED

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Novartis Pharmaceuticals

NCT01624636 TERMINATED

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Novartis Pharmaceuticals

NCT03558061 COMPLETED

Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration

Alkahest, Inc.

NCT01485588 COMPLETED

Safety and Tolerability Study for Age-Related Macular Degeneration

Iconic Therapeutics, Inc.

NCT03216538 COMPLETED

Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Feramda

NCT02418754 TERMINATED

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

Regeneron Pharmaceuticals

NCT03071055 COMPLETED

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

Southeast Clinical Research Associates, LLC

NCT03423823 COMPLETED

Ziv-aflibercept Efficacy in Better Regulating AMD

Kapil Kapoor

NCT02358889 COMPLETED

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Iconic Therapeutics, Inc.

NCT03465709 TERMINATED

Pegcetacoplan (APL-2) in Neovascular AMD

Apellis Pharmaceuticals, Inc.

NCT02613572 COMPLETED

Alpha Lipoic Acid in Geographic Atrophy

University of Pennsylvania

NCT03539549 COMPLETED

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

Allergan

NCT02903576 COMPLETED

Stem Cell Therapy for Outer Retinal Degenerations

Federal University of São Paulo

NCT00766649 COMPLETED

Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD

National Eye Institute (NEI)

NCT03626636 COMPLETED

A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

Allegro Ophthalmics, LLC

NCT03732287 COMPLETED

Cooling Anesthesia for Intravitreal Injection

Recens Medical, Inc.

NCT02555306 COMPLETED

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration

Santen Inc.

NCT01379560 COMPLETED

A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration

Sucampo Pharma Americas, LLC

NCT02571972 COMPLETED

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

Wills Eye

NCT01914159 COMPLETED

Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study

University Hospital, Bonn

NCT03446144 WITHDRAWN

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Ionis Pharmaceuticals, Inc.

NCT03479372 COMPLETED

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

PanOptica, Inc.

NCT02398500 TERMINATED

Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

Alcon Research

NCT02713204 COMPLETED

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Regeneron Pharmaceuticals

NCT02087085 TERMINATED

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

Allergan

NCT01397409 COMPLETED

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

Allergan

NCT02873351 WITHDRAWN

A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

Snyder, Robert W., M.D., Ph.D., P.C.

NCT01972763 COMPLETED

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

Northern California Retina Vitreous Associates

NCT03744767 COMPLETED

Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration

Dr Irmela MANTEL

NCT01021956 TERMINATED

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

Steba Biotech S.A.

NCT02302989 COMPLETED

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

Leonard Feiner, MD, PhD

NCT00658619 COMPLETED

Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)

Allergan

NCT01674569 COMPLETED

Pilot Study of X-82 in Patients With Wet AMD

Tyrogenex

NCT01213082 COMPLETED

ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)

University of California, Davis

NCT02355028 COMPLETED

LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration

Alcon, a Novartis Company

NCT02507388 COMPLETED

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Alcon Research

NCT01115556 COMPLETED

A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

Vitreous -Retina- Macula Consultants of New York

NCT02401945 COMPLETED

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Santen Inc.

NCT02022501 COMPLETED

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Santen Inc.

NCT01243086 COMPLETED

OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab

McMaster University

NCT02732899 COMPLETED

Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD

Maturi, Raj K., M.D., P.C.

NCT01134055 COMPLETED

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

GlaxoSmithKline

NCT01749891 COMPLETED

A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration

Allegro Ophthalmics, LLC

NCT00733304 COMPLETED

An Extension to Study MD7108240

GlaxoSmithKline

NCT00612456 COMPLETED

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

GlaxoSmithKline

NCT01362348 TERMINATED

12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)

GlaxoSmithKline

NCT01494805 COMPLETED

Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration

Lions Eye Institute, Perth, Western Australia

NCT01226628 COMPLETED

A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

Janssen Research & Development, LLC

NCT02563782 WITHDRAWN

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

Astellas Institute for Regenerative Medicine

NCT00931489 COMPLETED

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

Lawrence S. Morse, MD

NCT02357342 COMPLETED

Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

Maturi, Raj K., M.D., P.C.

NCT00935883 COMPLETED

Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)

Philip J. Rosenfeld, MD, PhD

NCT01162746 COMPLETED

Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Medical University of Vienna

NCT02511613 WITHDRAWN

Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

Ohr Pharmaceutical Inc.

NCT02181504 COMPLETED

A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration

Allergan

NCT01025232 TERMINATED

A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)

David M. Brown, M.D.

NCT01414153 COMPLETED

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

Lpath, Inc.

NCT02222207 TERMINATED

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration

Bayer

NCT02122159 WITHDRAWN

Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration

University of California, Los Angeles

NCT02121522 COMPLETED

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Boehringer Ingelheim

NCT02467634 TERMINATED

Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD

StemCells, Inc.

NCT02118831 COMPLETED

Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF

California Retina Consultants

NCT02181517 COMPLETED

A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Allergan

NCT02121353 COMPLETED

Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration

Pfenex, Inc

NCT01189019 TERMINATED

HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration

Anne Fung MD

NCT01849692 COMPLETED

ESBA1008 Microvolume Study

Alcon Research

NCT01926977 COMPLETED

Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

Arshad Khanani

NCT01796964 COMPLETED

Efficacy and Safety Study of ESBA1008 Versus EYLEA®

Alcon Research

NCT02314299 COMPLETED

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration

Stealth BioTherapeutics Inc.

NCT01632527 COMPLETED

Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

StemCells, Inc.

NCT00896779 COMPLETED

Lucentis in Advanced Macular Degeneration

Steven R. Sanislo

NCT01830790 TERMINATED

Effects of Sildenafil on Choroidal Thickness in AMD

Duke University

NCT01678963 COMPLETED

Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

Ohr Pharmaceutical Inc.

NCT00695318 TERMINATED

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

Alimera Sciences

NCT00913744 COMPLETED

Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion

ThromboGenics

NCT01016873 COMPLETED

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD

Oraya Therapeutics, Inc.

NCT01157715 COMPLETED

A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD

Chengdu Kanghong Biotech Co., Ltd.

NCT01175395 COMPLETED

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)

University of Illinois at Chicago

NCT00992563 COMPLETED

WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination

Alcon Research

NCT01304693 COMPLETED

ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

Alcon Research

NCT00605423 COMPLETED

The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot

Johns Hopkins University

NCT01242254 COMPLETED

A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD

Chengdu Kanghong Biotech Co., Ltd.

NCT01002950 COMPLETED

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

Kubota Vision Inc.

NCT01157065 COMPLETED

Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

Alcon Research

NCT00766337 TERMINATED

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

Santen Inc.

NCT00712491 TERMINATED

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Santen Inc.

NCT00793923 COMPLETED

A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD

Subhransu K. Ray, M.D., Ph.D.

NCT00713518 COMPLETED

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

Quark Pharmaceuticals

NCT00971464 COMPLETED

Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT01136252 COMPLETED

Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Hospital Universitari Vall d'Hebron Research Institute

NCT00940407 COMPLETED

Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration

Merry, Graham, M.D.

NCT00857259 TERMINATED

The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

Novartis Pharmaceuticals

NCT00776763 COMPLETED

Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab

Ophthalmological Association Edelweiss

NCT00805233 COMPLETED

Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration

Oregon Health and Science University

NCT00607750 COMPLETED

Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF

CoMentis

NCT00574093 COMPLETED

Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD

Fondazione G.B. Bietti, IRCCS

NCT00864838 COMPLETED

Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

University of Sao Paulo

NCT06961370 ACTIVE NOT RECRUITING

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Hoffmann-La Roche

NCT05904691 ACTIVE NOT RECRUITING

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Ocugenix Corporation

NCT06817343 ACTIVE NOT RECRUITING

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

Exegenesis Bio

NCT07406438 NOT YET RECRUITING

To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Shenzhen Kexing Pharmaceutical Co., Ltd.

NCT07330674 RECRUITING

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

Aptabio Therapeutics, Inc.

NCT01736059 ACTIVE NOT RECRUITING

Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

University of California, Davis

NCT01678872 ACTIVE NOT RECRUITING

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

Oxford BioMedica

NCT03178149 RECRUITING

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Astellas Institute for Regenerative Medicine

NCT06825858 ACTIVE NOT RECRUITING

A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Chengdu Origen Biotechnology Co., Ltd.

NCT05657301 ACTIVE NOT RECRUITING

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Chengdu Origen Biotechnology Co., Ltd.

NCT06319872 RECRUITING

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

University of Rochester

NCT05456828 ACTIVE NOT RECRUITING

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

AskGene Pharma, Inc.

NCT05803785 RECRUITING

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Benobio Co., Ltd.

NCT06198413 ACTIVE NOT RECRUITING

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Innostellar Biotherapeutics Co.,Ltd

NCT07024732 NOT YET RECRUITING

A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration

Eyevensys

NCT05147701 RECRUITING

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

The Foundation for Orthopaedics and Regenerative Medicine

NCT05698329 ACTIVE NOT RECRUITING

Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

AiViva BioPharma, Inc.

NCT06832657 NOT YET RECRUITING

Study of JMKX003948 Ophthalmic Suspension in Healthy Participants

Jemincare

NCT06132035 RECRUITING

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Caregen Co. Ltd.

NCT06213038 RECRUITING

A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Youxin Chen

NCT06623279 NOT YET RECRUITING

Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial

HuidaGene Therapeutics Co., Ltd.

NCT05611424 NOT YET RECRUITING

Gene Therapy for Wet AMD

Frontera Therapeutics

NCT05445063 RECRUITING

Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration

Beijing Tongren Hospital

NCT07594236 RECRUITING

Phase 1 Study of C.001 in Retinal Degeneration

Cellio Therapeutics Inc

NCT05903794 COMPLETED

A Study of EXG102-031 in Patients With wAMD (Everest)

Exegenesis Bio

NCT07484074 COMPLETED

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

Ollin Biosciences, Inc.

NCT05953012 COMPLETED

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

PharmAbcine

NCT05643118 COMPLETED

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

Olix Pharmaceuticals, Inc.

NCT06969001 COMPLETED

Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

SCAI Therapeutics

NCT04635800 COMPLETED

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Novartis Pharmaceuticals

NCT02230228 COMPLETED

Phase 1 Safety Study of ALK-001 in Healthy Volunteers

Alkeus Pharmaceuticals, Inc.

NCT03814291 COMPLETED

A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

Innovent Biologics (Suzhou) Co. Ltd.

NCT03585556 COMPLETED

AAVCAGsCD59 for the Treatment of Wet AMD

Janssen Research & Development, LLC

NCT03144999 COMPLETED

Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59

Janssen Research & Development, LLC

NCT00709527 COMPLETED

ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration

Ophthotech Corporation

NCT00950638 COMPLETED

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Ophthotech Corporation

NCT04422899 COMPLETED

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

AiViva BioPharma, Inc.

NCT05345769 COMPLETED

Safety and Efficacy of AM712 in Patients with NAMD

AffaMed Therapeutics Limited

NCT05262244 COMPLETED

Targeted Fluorescence Imaging in AMD

University Medical Center Groningen

NCT01691261 COMPLETED

A Study of Implantation of Retinal Pigment Epithelium in Subjects with Acute Wet Age Related Macular Degeneration

Moorfields Eye Hospital NHS Foundation Trust

NCT05639530 COMPLETED

A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Innovent Biologics (Suzhou) Co. Ltd.

NCT03630315 COMPLETED

CLN-0046: Treatment of AMD Subjects With OTX-TKI

Ocular Therapeutix, Inc.

NCT04884399 COMPLETED

Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

Shanghai Biomabs Pharmaceutical Co., Ltd.

NCT03790852 TERMINATED

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Kodiak Sciences Inc

NCT00782093 COMPLETED

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Ophthotech Corporation

NCT04989699 COMPLETED

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Ocular Therapeutix, Inc.

NCT04002310 TERMINATED

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Boehringer Ingelheim

NCT02204683 COMPLETED

Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration

University of Nebraska

NCT03748784 COMPLETED

ADVM-022 Intravitreal Gene Therapy for Wet AMD

Adverum Biotechnologies, Inc.

NCT04747197 COMPLETED

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

EyePoint Pharmaceuticals, Inc.

NCT04594681 TERMINATED

A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration

Kyowa Kirin Co., Ltd.

NCT05667688 COMPLETED

Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85

RBP4 Pty Ltd

NCT03835884 COMPLETED

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

Aerie Pharmaceuticals

NCT05105607 COMPLETED

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

Ashvattha Therapeutics, Inc.

NCT01003691 COMPLETED

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

Pfizer

NCT04919096 WITHDRAWN

Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration

Clover Biopharmaceuticals AUS Pty

NCT02867735 COMPLETED

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

Novartis Pharmaceuticals

NCT04537884 COMPLETED

Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

Unity Biotechnology, Inc.

NCT04058535 COMPLETED

Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD

Alteogen, Inc.

NCT04894071 COMPLETED

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

Smilebiotek Zhuhai Limited

NCT04370379 COMPLETED

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

Innovent Biologics (Suzhou) Co. Ltd.

NCT04151212 COMPLETED

A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration

Bio-Thera Solutions

NCT03777254 COMPLETED

Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration

RemeGen Co., Ltd.

NCT04246866 COMPLETED

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

Gemini Therapeutics, Inc.

NCT02848313 COMPLETED

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Stealth BioTherapeutics Inc.

NCT02461771 COMPLETED

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

Apellis Pharmaceuticals, Inc.

NCT03387566 COMPLETED

A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration

Huabo Biopharm Co., Ltd.

NCT02452385 SUSPENDED

Phase 1 Study of CM082 in Patients With wAMD

AnewPharma

NCT03249740 COMPLETED

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

Graybug Vision

NCT03312283 COMPLETED

Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

Qilu Pharmaceutical Co., Ltd.

NCT03335852 COMPLETED

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

Allergan

NCT02591914 COMPLETED

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

Retinal Consultants of Arizona

NCT01024998 COMPLETED

Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Genzyme, a Sanofi Company

NCT01271270 COMPLETED

Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration

National Eye Institute (NEI)

NCT02530918 COMPLETED

Study of DS-7080a for the Treatment of Macular Degeneration

Daiichi Sankyo

NCT02859766 COMPLETED

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD

Allergan

NCT01072214 COMPLETED

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

GlaxoSmithKline

NCT01051700 COMPLETED

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

GlaxoSmithKline

NCT00659555 COMPLETED

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

GlaxoSmithKline

NCT01154062 COMPLETED

A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration

GlaxoSmithKline

NCT02543229 COMPLETED

Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD

Opthea Limited

NCT01301443 COMPLETED

Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)

Oxford BioMedica

NCT01941082 COMPLETED

A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration

Hoffmann-La Roche

NCT02022540 COMPLETED

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

PanOptica, Inc.

NCT02076919 COMPLETED

First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration

Alcon Research

NCT01835015 COMPLETED

Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration

Alcon Research

NCT02130531 COMPLETED

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Kubota Vision Inc.

NCT01997164 COMPLETED

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Regeneron Pharmaceuticals

NCT00726466 WITHDRAWN

Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration

Vitreous -Retina- Macula Consultants of New York

NCT02332941 COMPLETED

Treatment -Resistant Neovascular Age-Related Macular Degeneration

Washington University School of Medicine

NCT00877032 COMPLETED

Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration

Pfizer

NCT01186432 COMPLETED

Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration (AMD)

Forsight Vision4

NCT02061865 COMPLETED

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Regeneron Pharmaceuticals

NCT01086761 TERMINATED

Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

Allergan

NCT01922128 COMPLETED

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

MacuCLEAR, Inc.

NCT00791570 COMPLETED

Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy

Osaka University

NCT01033721 COMPLETED

Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration

Paloma Pharmaceuticals, Inc.

NCT01177644 WITHDRAWN

Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD

Forsight Vision4

NCT01255462 COMPLETED

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

Novartis Pharmaceuticals

NCT01013376 COMPLETED

A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD

MacuCLEAR, Inc.

NCT04853251 RECRUITING

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Genentech, Inc.

NCT06795048 ACTIVE NOT RECRUITING

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Hoffmann-La Roche

NCT07456826 ENROLLING BY INVITATION

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

Harrow Inc

NCT06970665 RECRUITING

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Astellas Pharma Inc

NCT07403825 NOT YET RECRUITING

Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material

Biobizkaia Health Research Institute

NCT07367282 NOT YET RECRUITING

Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration

Junyeop Lee

NCT07365371 NOT YET RECRUITING

A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

NCT06742307 RECRUITING

Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration

Hospital Authority, Hong Kong

NCT07187804 NOT YET RECRUITING

Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization

Kim's Eye Hospital

NCT06875245 RECRUITING

Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals

Faculty Hospital Kralovske Vinohrady

NCT05093374 RECRUITING

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Medical University of Vienna

NCT06683950 RECRUITING

Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

Kim's Eye Hospital

NCT06591598 COMPLETED

A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

Bayer

NCT04679935 COMPLETED

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Novartis Pharmaceuticals

NCT07090044 COMPLETED

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

Retina Research Institute, LLC

NCT05941715 COMPLETED

Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration

Medical University of Graz

NCT04774926 COMPLETED

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

Novartis Pharmaceuticals

NCT05269966 COMPLETED

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Novartis Pharmaceuticals

NCT05832996 COMPLETED

Cool vs Room-temperature Artificial Tears

University of Iowa

NCT06708624 COMPLETED

Ocular Safety and Usability Study for FYB201 PFS

Formycon AG

NCT06708637 COMPLETED

Ocular Safety and Usability Study for FYB203 PFS

Formycon AG

NCT05473715 TERMINATED

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

Bayer

NCT05710471 COMPLETED

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

The University of Hong Kong

NCT06330220 COMPLETED

Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity

Seoul National University Hospital

NCT04075136 WITHDRAWN

Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

Wake Forest University Health Sciences

NCT02305238 COMPLETED

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

Bayer

NCT02581891 COMPLETED

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

Bayer

NCT04563299 TERMINATED

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

Retina Vitreous Associates of Florida

NCT04761341 COMPLETED

FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment

Insel Gruppe AG, University Hospital Bern

NCT04698850 WITHDRAWN

Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation

Faculty Hospital Kralovske Vinohrady

NCT02125864 COMPLETED

Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept

Oslo University Hospital

NCT03022292 COMPLETED

The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy

University of California, Los Angeles

NCT04287348 TERMINATED

Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept

Vista Klinik

NCT03117634 COMPLETED

An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy

Singapore National Eye Centre

NCT02689518 COMPLETED

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

University of California, San Diego

NCT01573572 COMPLETED

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

Bausch & Lomb Incorporated

NCT01006538 COMPLETED

Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)

King's College Hospital NHS Trust

NCT02120950 COMPLETED

Aflibercept in Polypoidal Choroidal Vasculopathy

Bayer

NCT04018482 COMPLETED

Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study)

California Retina Consultants

NCT01972789 COMPLETED

Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)

Novartis Pharmaceuticals

NCT01775124 COMPLETED

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Novartis Pharmaceuticals

NCT02321839 COMPLETED

Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

Nagoya City University

NCT01464723 COMPLETED

Study EvAluating Genotypes While Using Lucentis 2

University of California, San Diego

NCT01986907 COMPLETED

Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

Novartis Pharmaceuticals

NCT01846273 COMPLETED

Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)

Novartis Pharmaceuticals

NCT02130024 COMPLETED

A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients

Novartis Pharmaceuticals

NCT02257632 COMPLETED

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Novartis Pharmaceuticals

NCT01958918 COMPLETED

Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD

Novartis Pharmaceuticals

NCT03169660 COMPLETED

Intravitreal Aflibercept for Submacular Hemorrhage

Kim's Eye Hospital

NCT02140411 COMPLETED

Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.

Novartis Pharmaceuticals

NCT02161575 COMPLETED

Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD

Novartis Pharmaceuticals

NCT03804099 COMPLETED

Effect Aflibercept on Ocular Perfusion

Augenabteilung Allgemeines Krankenhaus Linz

NCT01896284 COMPLETED

Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor

Barcelona Macula Foundation

NCT02309281 COMPLETED

Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab

Vista Klinik

NCT01495221 COMPLETED

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

Vitreous -Retina- Macula Consultants of New York

NCT01617148 COMPLETED

Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept

Rishi Singh

NCT03552770 COMPLETED

Single or Combined Protocols for NV-AMD

University Hospital of Ferrara

NCT02441816 COMPLETED

VITAL - Individualising Therapy for Neovascular AMD With Aflibercept

Moorfields Eye Hospital NHS Foundation Trust

NCT02002377 TERMINATED

Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections

Unity Health Toronto

NCT02944227 COMPLETED

Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration

Seoul National University Hospital

NCT03409250 COMPLETED

SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

Vista Klinik

NCT03393767 COMPLETED

Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD

Vista Klinik

NCT01722045 COMPLETED

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

Regeneron Pharmaceuticals

NCT02843490 COMPLETED

Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration

Johannes Gutenberg University Mainz

NCT02577107 COMPLETED

Head to Head Study of Anti-VEGF Treatment.

Novartis Pharmaceuticals

NCT01863199 COMPLETED

Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

Retinal Consultants of Arizona

NCT01988662 COMPLETED

UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)

Novartis Pharmaceuticals

NCT02142296 COMPLETED

Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT02634970 WITHDRAWN

CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab

Novartis Pharmaceuticals

NCT01543568 COMPLETED

Study for Recalcitrant Age Related Macular Degeneration

David M. Brown, M.D.

NCT02246829 COMPLETED

Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START

University Hospital, Bordeaux

NCT01810042 COMPLETED

Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab

Pusan National University Hospital

NCT01950741 COMPLETED

Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy

Pusan National University Hospital

NCT01983579 TERMINATED

TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection

Sensimed AG

NCT01824225 COMPLETED

Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration

Nihon University

NCT01319188 TERMINATED

Ranibizumab and the Risk of Arterial Thromboembolic Events

Ural State Medical University

NCT01500915 COMPLETED

FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration

Institut de la Macula y la Retina

NCT01127360 COMPLETED

LUCAS (Lucentis Compared to Avastin Study)

Oslo University Hospital

NCT02060604 COMPLETED

Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration

Università degli Studi di Brescia

NCT01148511 COMPLETED

Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)

Novartis Pharmaceuticals

NCT01831947 COMPLETED

Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

NCT01453920 COMPLETED

Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing

University Health Network, Toronto

Full Age-Related Macular Degeneration Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only